Warning letter
York Pharmaceutical Inc.: warning letter of Apr 24, 2000
FDA warning letter UCM068367 · Kansas City District Office
Key facts
| Reference number | UCM068367 |
|---|---|
| Company | York Pharmaceutical Inc. |
| Subject | OTC Drug Manufacturing Facility/cGMP |
| Issue date | Apr 24, 2000 |
| Posted date | Apr 24, 2000 |
| Issuing office | Kansas City District Office |
| Product type | Drugs |
| CFR sections cited | 211.84(d)(2), 211.166(b), 211.165(e), 211.188(b), 21, 211, 211.67, 211.84, 211.110, 211.192 |
| Country | 3 |
| Inspection city | Kansas City |
| Inspection ZIP | 66103-1405 |
| Inspection start date | Mar 20, 2000 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: